Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • ASCO and others release HER2 and other cancer treatment guidance

    The College of American Pathologists, the American Society for Clinical Pathology and the American Society of Clinical Oncology published an evidence-based guideline on HER2 testing for patients with gastroesophageal …

    Published on 12/5/2016
  • Orchard, UCLA receive CIRM grant

    CIRM awarded Orchard and researchers from the university a $20 million grant to fund a clinical trial of an autologous ex vivo lentiviral gene therapy to treat severe combined immunodeficiency due to adenosine deaminase…

    Published on 12/5/2016
  • TESLA initiative launches

    The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute partnered to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage …

    Published on 12/5/2016
  • Alexion Soliris eculizumab news

    Alexion said it was delaying its 3Q16 10-Q filing while it investigates a former employee's allegations that company personnel engaged in sales practices "inconsistent" with Alexion's policies. The allegations concern …

    Published on 11/21/2016
  • Chi-Med, Shanghai Pharmaceuticals news

    Shanghai Hutchison Pharmaceuticals Ltd., a JV between Chi-Med and Shanghai Traditional Chinese Medicine Co. Ltd., a subsidiary of Shanghai Pharmaceuticals, received $59.5 million from the Shanghai government under a …

    Published on 11/21/2016
  • Novavax restructuring

    Novavax will reduce headcount by 164 (30%) to about 372 and will focus on its ongoing Phase III Prepare trial to vaccinate infants against respiratory syncytial virus (RSV) via maternal immunization. Last quarter, the …

    Published on 11/21/2016
  • Roche launches imCORE Network

    Roche said it launched its cancer immunotherapy Centers of Research Excellence (imCORE) Network with researchers from 21 academic institutions. The company said it will invest up to CHF100 million ($100.3 million) to …

    Published on 11/21/2016
  • Takeda infectious news

    Takeda said it will donate 1 billion ($9.3 million) to implement the United Nations Foundation's Global Measles Vaccination for Children program, which is aiming to provide vaccines to 5.4 million children in about 40 …

    Published on 11/21/2016
  • uniQure restructuring news

    uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save 5-6 million ($5.4-$6.4 million) annually, while reprioritizing …

    Published on 11/21/2016
  • AbbVie, Coherus biosimilars news

    The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office denied Coherus' inter partes review petition challenging U.S. Patent No. 9,114,166 covering autoimmune drug Humira adalimumab from AbbVie. PTAB …

    Published on 11/14/2016
  • Astellas pharmaceuticals news

    Astellas established a Patient Experience Organization in the Americas to incorporate patient feedback and advocacy. The organization will create a measurable framework to develop and evaluate strategies, policies and …

    Published on 11/14/2016
  • CHDI Foundation, Critical Path neurology news

    CHDI and Critical Path partnered to form the HD Regulatory Science Consortium. The goal of the consortium is to "clearly define regulatory pathways" for approval of Huntington's disease therapies. Critical Path will be …

    Published on 11/14/2016
  • Opexa restructuring

    Opexa reduced headcount by 8 (40%) to 12 after the company's Tcelna imilecleucel-T missed the primary and secondary endpoints in the Phase IIb Abili-T trial to treat secondary progressive multiple sclerosis (SPMS). …

    Published on 11/7/2016
  • Celgene, Epic Sciences, Foundation Medicine, Genentech, Guardant Health, Personal Genome Diagnostics, Sage Bionetworks, Seven Bridges, Thermo Fisher, AstraZeneca, Eli Lilly, Novartis, Pfizer, ...

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Epic Sciences Inc., La Jolla, Calif. Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. Genentech Inc., South San Francisco, Calif. Guardant Health Inc., Redwood City, …

    Published on 10/24/2016
  • Clarus Therapeutics, Lipocine endocrine/metabolic, drug delivery news

    Clarus Therapeutics Inc., Northbrook, Ill. Lipocine Inc. (NASDAQ:LPCN), Salt Lake City, Utah Business: Endocrine/Metabolic, Drug delivery Clarus said the U.S. District Court for the District of Delaware dismissed a …

    Published on 10/24/2016
  • CosmosID Inc bioinformatics, cancer news

    CosmosID Inc, Rockville, Md. Business: Bioinformatics, Cancer CosmosID committed to provide its MetaGenID automated bioinformatics platform to the Cancer Moonshot Initiative. The platform will support five trials to …

    Published on 10/24/2016
  • MRIGlobal, Thermo Fisher, Arizona State University, U.S. Department of Health and Human Services other news

    MRIGlobal, Kansas City, Mo. Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Arizona State University, Phoenix, Ariz. U.S. Department of Health and Human Services, Washington, D.C. Business: Other HHSs …

    Published on 10/24/2016
  • Amgen, Sanofi, U.S. Department of Health and Human Services other news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France U.S. Department of Health and Human Services, Washington, D.C. Business: Other HHSs Biomedical Advanced Research and …

    Published on 10/17/2016
  • ASCO cancer news

    American Society of Clinical Oncology, Alexandria, Va. Business: Cancer ASCO issued a worldwide, screening guideline for cervical cancer. The guideline provides evidence-based screening recommendations, follow-up for …

    Published on 10/17/2016
  • Medivir cancer news

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Cancer Medivir will reduce headcount by 30 (25%) to about 90 and focus its pipeline exclusively on cancer. Cuts will come from the early research organization and …

    Published on 10/17/2016
  • Merrimack cancer news

    Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Business: Cancer Merrimack is reducing headcount by 22% to prioritize R&D on a focused set of systems biology-derived oncology products. Merrimack said cuts…

    Published on 10/17/2016
  • Mylan inflammation news

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Inflammation Mylan will pay $465 million to the U.S. Department of Justice and other government entities to resolve questions about the classification of Mylans EpiPen …

    Published on 10/17/2016
  • New WuXi supply/service news

    New WuXi Life Science Ltd., Shanghai, China Business: Supply/Service New WuXis WuXi AppTec subsidiary opened a biomanufacturing facility in Philadelphia, Pa., which the company plans to use for manufacturing cell …

    Published on 10/17/2016
  • Spark Therapeutics ophthalmic news

    Spark Therapeutics Inc. (NASDAQ:ONCE), Philadelphia, Pa. Business: Ophthalmic Spark launched the Identify Your Inherited Retinal Disease initiative in the U.S. to provide patients with genetic testing for more than 30 …

    Published on 10/17/2016
  • Trinity diagnostic news

    Trinity Biotech plc (NASDAQ:TRIB), Dublin, Ireland Business: Diagnostic Trinity withdrew its 510(k) submission and will begin a strategic review to determine the best use of its Meritas Troponin-I test technology. The …

    Published on 10/17/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993